Recurrent Renal Cell Carcinoma Clinical Trial
Official title:
A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma
This randomized phase II trial studies the side effects and how well Akt inhibitor MK2206 or everolimus works in treating patients with kidney cancer that does not respond to treatment. Akt inhibitor MK2206 and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Everolimus may also stop the growth of kidney cancer by blocking blood flow to the tumor. It is not yet known whether Akt inhibitor MK2206 or everolimus is more effective in treating kidney cancer.
PRIMARY OBJECTIVES:
I. To assess progression free survival (PFS) of vascular endothelial growth factor (VEGF)
therapy refractory renal cell carcinoma (RCC) patients who receive either MK-2206 (Akt
inhibitor MK-2206) or everolimus.
II. To assess safety of MK-2206 in patients with VEGF therapy refractory RCC.
SECONDARY OBJECTIVES:
I. To assess overall response rate (ORR) and overall survival (OS). (Clinical) II. To assess
time to treatment failure (TTF). (Clinical) III. To determine whether baseline AKT activation
is predictive for clinical benefit after treatment with MK-2206 or everolimus.
(Pre-clinical/exploratory) IV. To determine whether circulating cytokines and angiogenic
factors predict for clinical benefit after treatment with MK-2206 or everolimus.
(Pre-clinical/exploratory) V. To assess impact of karyotype on outcome in patients treated
with MK-2206 or everolimus. (Pre-clinical/exploratory)
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive Akt inhibitor MK2206 orally (PO) on days 1, 8, 15, and 22. Courses
repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Patients
who are progression free after 1 year may receive a 12 week study drug supply of Akt
inhibitor MK2206.
ARM II: Patients receive everolimus PO once daily (QD) on days 1-28. Courses repeat every 4
weeks in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02664883 -
Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer
|
||
Terminated |
NCT01198158 -
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy
|
Phase 3 | |
Completed |
NCT00378703 -
Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer
|
Phase 2 | |
Completed |
NCT03229278 -
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
|
Phase 1 | |
Recruiting |
NCT05119335 -
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
Completed |
NCT00278395 -
Vorinostat in Treating Patients With Kidney Cancer
|
Phase 2 | |
Terminated |
NCT02170389 -
Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer
|
N/A | |
Recruiting |
NCT05641935 -
Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation
|
Phase 2 | |
Active, not recruiting |
NCT04514484 -
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
|
Phase 1 | |
Completed |
NCT01727089 -
Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
|
Phase 2 | |
Completed |
NCT00499135 -
Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT02035358 -
Immunotherapy Study for Metastatic Renal Cell Cancer
|
Phase 1 | |
Completed |
NCT01131234 -
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00126503 -
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02867592 -
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
|
Phase 2 | |
Active, not recruiting |
NCT01767636 -
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
|
Phase 2 | |
Terminated |
NCT02542202 -
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer
|
N/A | |
Completed |
NCT01548482 -
Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
|
Phase 1 | |
Completed |
NCT01522820 -
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
|
Phase 1 | |
Completed |
NCT00126490 -
Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
|
Phase 2 |